



National  
Library  
of Medicine

My NCBI [Sign In] [Register]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search **PubMed**

for sulphasalazine and psoriasis and topical

**Go!** **Clear** Save Search

Limits Preview/Index History Clipboard Details

Display **Summary** Show 20 Sort by Send to

All: 6 Review: 1

About Entrez  
NCBI Toolbar

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Items 1 - 6 of 6

One page

**1:** Schmitt J, Wozel G.

Related Articles, Links

**2:** [Psoriasis arthritis--long-term treatment of two patients with leflunomide]J Dtsch Dermatol Ges. 2004 Sep;2(9):763-6. German.  
PMID: 15279220 [PubMed - indexed for MEDLINE]**3:** Piquero-Casals J, Fonseca de Mello AP, Dal Coletto C, Fonseca Takahashi MD, Simonsen Nico MM.

Related Articles, Links

**4:** Using oral tetracycline and topical betamethasone valerate to treat acrodermatitis continua of hallopeau.Cutis. 2002 Aug;70(2):106-8.  
PMID: 12234156 [PubMed - indexed for MEDLINE]**5:** Bouyssou-Gauthier ML, Bedane C, Boulinguez S, Bonnetblanc JM.

Related Articles, Links

**6:** Photosensitivity with sulfasalazopyridine hypersensitivity syndrome.Dermatology. 1999;198(4):388-90.  
PMID: 10449939 [PubMed - indexed for MEDLINE]**7:** Goupille P, Soutif D, Valat JP.

Related Articles, Links

**8:** Treatment of psoriatic arthropathy.Semin Arthritis Rheum. 1992 Jun;21(6):355-67. Review.  
PMID: 1626281 [PubMed - indexed for MEDLINE]**9:** Ng CS, Wolfsen HC, Kozarek RA, Brubacher LL, Kayne AL.

Related Articles, Links

**10:** Chronic parastomal ulcers: spectrum of dermatoses.J ET Nurs. 1992 May-Jun;19(3):85-90.  
PMID: 1350739 [PubMed - indexed for MEDLINE]**11:** Gupta AK, Ellis CN, Siegel MT, Duell EA, Griffiths CE, Hamilton TA, Nickoloff BJ, Voorhees JJ.

Related Articles, Links

**12:** Sulfasalazine improves psoriasis. A double-blind analysis.Arch Dermatol. 1990 Apr;126(4):487-93.  
PMID: 1690970 [PubMed - indexed for MEDLINE]Display **Summary**

Show 20 Sort by

Send to


Write to the Help Desk

NCBI | NLM | NIH

Department of Health &amp; Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Mar 28 2006 06:29:55



National  
Library  
of Medicine

My NCBI  
[Sign In] [Register]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search 

for lisophyline and psoriasis and topical and auranofin

Limits

The following term was not found and ignored: lisophyline.

See [Details](#).

Display  Summary

Show

All: 4  Review: 1

Items 1 - 4 of 4

One page.

1: [Helm KF, Marks JG Jr, Leyden JJ, Guzzo C, Krueger GG, Griffiths TW, Griffiths CE.](#)

[Related Articles](#), [Links](#)

Topical auranofin ointment for the treatment of plaque psoriasis.

*J Am Acad Dermatol.* 1995 Sep;33(3):517-9. No abstract available.

PMID: 7657878 [PubMed - indexed for MEDLINE]

2: [Marks JG Jr, Helm KF, Krueger GG, Griffiths CE, Guzzo CA, Leyden JJ.](#)

[Related Articles](#), [Links](#)

Contact dermatitis from topical auranofin.

*J Am Acad Dermatol.* 1995 May;32(5 Pt 1):813-4. No abstract available.

PMID: 7722032 [PubMed - indexed for MEDLINE]

3: [Thomas RE, Papandrea RA.](#)

[Related Articles](#), [Links](#)

Treatment of psoriasis with topical auranofin.

*Med J Aust.* 1993 May 17;158(10):720. No abstract available.

PMID: 8487703 [PubMed - indexed for MEDLINE]

4: [Goupille P, Soutif D, Valat JP.](#)

[Related Articles](#), [Links](#)

Treatment of psoriatic arthropathy.

*Semin Arthritis Rheum.* 1992 Jun;21(6):355-67. Review.

PMID: 1626281 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 28 2006 06:39:55



National  
Library  
of Medicine

My NCBI   
[Sign In] [Register]

All Databases PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search **PubMed**

for

**Go!** **Clear**

Limits Preview/Index History Clipboard Details

Display **Abstract** Show **20** Sort by Send to

All: 1 Review: 1

About Entrez  
NCBI Toolbar

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Related Articles, Links

**1: Semin Arthritis Rheum. 1992 Jun;21(6):355-67.**

## Treatment of psoriatic arthropathy.

**Goupille P, Soutif D, Valat JP.**

Department of Rheumatology, University of Tours, Trousseau Hospital, France.

Psoriatic arthritis develops in 5% of patients with cutaneous psoriasis. Management is similar to that of other chronic inflammatory joint diseases, and the characteristic features of psoriatic arthritis should be considered: the disease is usually mild, with unpredictable flares and remissions, and skin disease is a concomitant feature. Nonsteroidal antiinflammatory agents are the mainstay of therapy and usually provide adequate control. Among long-term treatments, parenteral gold salts, methotrexate, and azathioprine have been shown to be effective. Retinoids are often used in patients with extensive skin lesions. Other treatments are currently being evaluated (auranofin, colchicine, D-penicillamine, sulfasalazine, cyclosporine, and gamma-interferon). Antimalarials are difficult to handle and may cause progression of skin lesions. Topical treatments are indicated in every case. Indications depend on the specific features of psoriatic arthritis, the clinical pattern, and the severity of the condition.

### Publication Types:

- Review

PMID: 1626281 [PubMed - indexed for MEDLINE]

Display **Abstract** Show **20** Sort by Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 28 2006 06:29:55



National  
Library  
of Medicine

My NCBI  
[Sign In] [Register]

All Databases      PubMed      Nucleotide      Protein      Genomes      Structure      OMIM      PMC      Journals      Books

Search **PubMed**

for

**Go** **Clear**

Limits      Preview/Index      History      Clipboard      Details

Display **Abstract** Show **20** Sort by Send to

All: 1 Review: 0

About Entrez  
NCBI Toolbar

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Related Articles, Links

**1: J Rheumatol. 1995 May;22(5):894-8.**

Comment in:

- J Rheumatol. 1996 Apr;23(4):791-2.

## Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial.

**Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, McCune WJ.**

Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA.

**OBJECTIVE.** Psoriatic arthritis (PsA) is often poorly responsive to 2nd line antirheumatic drug therapy. Sulfasalazine has recently gained wide acceptance in the treatment of rheumatoid arthritis, and beneficial effects have also been noted in ankylosing spondylitis and reactive arthritis. We report a double blind placebo controlled study of sulfasalazine in PsA. **METHODS.** Twenty-four patients with active PsA were randomized to receive either sulfasalazine (3 g/day) ( $n = 10$ ) or placebo ( $n = 14$ ) for 8 weeks, in a double blind manner, followed by an 8 week open label crossover phase for nonresponding placebo patients.

**RESULTS.** Compared with placebo controls, sulfasalazine treated patients were significantly improved at Weeks 4 and 8 with respect to physician ( $p < 0.01$ ) and patient ( $p < 0.05$ ) global assessments. Duration of morning stiffness was significantly decreased at Week 8 ( $p < 0.01$ ). Clinical variables of disease activity returned to baseline after a 4 week drug washout period in 5 evaluable patients. Six patients in the placebo group crossed over to an 8 week open label phase and demonstrated significant improvements in joint scores, 50 ft walking time, and global patient assessment. Sulfasalazine treated patients also showed significant improvements in cutaneous involvement. **CONCLUSION.**

Sulfasalazine was effective in PsA, with efficacy observed as early as the 4th week of treatment. Longterm studies are needed to determine whether such therapy can modify disease outcome.

**Publication Types:**

- Clinical Trial
- Randomized Controlled Trial

**PMID: 8587078 [PubMed - indexed for MEDLINE]**

Display **Abstract** Show **20** Sort by Send to

[Write to the Help Desk](#)